Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate, Rivastigmine, or Haloperidol for Hypoactive ICU Delirium
NCT00599287Phase 3Terminated
- Start
- Feb 2008
- Primary completion
- May 2008
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of methylphenidate hydrochloride extended-release chewable tablet, rivastigmine, haloperidol in delirium. Started Feb 2008; status: terminated.
02
Drugs
methylphenidate hydrochloride extended-release chewable tabletrivastigminehaloperidol
03
Conditions
delirium
Beyond the preview
Go deeper on NCT00599287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00599287.